What improved

• The prostate lesion has almost completely regressed. The 2026 scan reports no abnormal PSMA-avid lesion in the prostate gland.
• The previously large abdominal and pelvic lymph nodes have shrunk substantially and are now PSMA non-avid. These are described as likely residual treated metastatic nodes.
• No clear PSMA-avid disease is reported in organs such as liver, kidneys, adrenal glands, or elsewhere in the soft tissues.

What is concerning

• There are extensive PSMA-avid sclerotic bone metastases, involving both the axial skeleton and limbs, including the sternum, right scapula, right iliac bone, and right tibia.
• The report specifically says there has been interval development of new bone lesions, meaning skeletal metastatic disease has progressed despite the improvement in the prostate and lymph nodes.
• This likely explains the reported bone pain.

Lungs

Overall meaning

• Good local and nodal response
• Persistent and progressive bone-dominant metastatic disease
• No major new PSMA-avid disease outside the skeleton

Important next discussion with the medical oncologist

1. Whether he meets criteria for Lu-177 PSMA radioligand therapy.
2. Whether androgen-deprivation therapy and any androgen-receptor drug should continue or be changed.
3. Bone-protective treatment, commonly denosumab or zoledronic acid where appropriate, plus calcium/vitamin D and dental assessment.
4. Pain control and whether a painful or high-risk bone site needs radiotherapy.
5. Monitoring with PSA, alkaline phosphatase, complete blood count, renal and liver tests.

Appointment Summary: PSMA PET/CT Scan Findings

Main scan result

1. Prostate and lymph nodes: marked improvement

• No abnormal PSMA-avid lesion remains visible in the prostate gland.
• Previously seen prostate lesion has almost completely regressed.
• Previously enlarged metastatic abdominal and pelvic lymph nodes have decreased substantially in size and are now PSMA non-avid.
• These lymph nodes are described as likely residual treated metastatic nodes.

2. Bones: active widespread metastatic disease

• Sternum
• Right scapula
• Right iliac bone
• Right tibia
• Other axial and appendicular skeletal sites

3. Lungs and other organs

• Tiny lung nodules and mild lung collapse/scarring-type changes are PSMA non-avid.
• No pleural fluid.
• No PSMA-avid disease reported in the liver, pancreas, spleen, kidneys, adrenal glands, bowel, or elsewhere in soft tissues.
• Mild symmetric urinary-bladder wall thickening is noted.
• No abnormal PSMA-avid lesion reported in the brain, although PSMA PET is not the preferred test for assessing brain disease.

Overall impression

• Favourable response: prostate lesion and previously involved lymph nodes.
• Ongoing/progressive disease: widespread, active bone metastases, including new lesions.
• No other PSMA-avid disease elsewhere in the body on this study.

Report recommendation

Questions for the oncology appointment

1. Is the cancer now considered metastatic castration-resistant prostate cancer, and what is the current treatment goal?
2. Is he eligible for Lu-177 PSMA radioligand therapy? What tests or criteria are still needed?
3. What treatment is recommended for the painful bone metastases, including possible localized radiation?
4. Should bone-strengthening therapy be started or continued, such as denosumab or zoledronic acid?
5. What blood tests should be monitored before further therapy: PSA, testosterone, CBC, kidney function, liver function, alkaline phosphatase, calcium?
6. Is there a fracture or spinal-cord-compression risk from any of the involved bones?
7. The records list Gleason scores of both 4+3=7 in the 2022 report and 4+4=8 in the 2026 report. Which is correct according to the original biopsy/pathology?

1. The PSMA PET scan first checks whether the cancer deposits display PSMA.
2. Lu-177 is attached to a PSMA-seeking molecule.
3. It travels to PSMA-positive cancer cells and delivers short-range radiation directly there.

How concrete are the chances?

• The cancer remained controlled on scans for a median of 8.7 months with Lu-177 PSMA plus standard treatment, versus 3.4 months with standard treatment alone.
• Median overall survival was 15.3 months vs 11.3 months in that particular trial population. This means a group-level survival benefit of roughly 4 months, not that it predicts an individual person's lifespan.
• About half of patients achieved a major PSA fall, commonly defined as a drop of at least 50%.
• Where measurable soft-tissue lesions were present, about 49% had objective shrinkage. Bone response is more difficult to measure by conventional size criteria.
• Some people have a large and durable response, some have temporary benefit, and some do not respond. The VISION trial showed that the treatment improves both scan-based disease control and survival in appropriately selected patients.

What this scan suggests for him

• The active bone metastases are described as PSMA-avid, so the treatment has a visible target.
• Disease appears mainly skeletal, which matches the nuclear medicine physician's recommendation.
• The prostate lesion and lymph nodes have responded well, with no current PSMA-avid prostate lesion and shrinking, non-avid nodes.
• No PSMA-avid liver or other organ metastases are reported.

• Bone disease is extensive. Bone marrow makes blood cells, so doctors must assess whether there is enough marrow reserve for treatment.
• He has recently completed chemotherapy, so the current hemoglobin, white-cell/neutrophil count, platelet count, kidney function and liver function matter a great deal.
• The team should confirm his testosterone is at castrate level and clarify prior androgen-receptor drugs, such as abiraterone, enzalutamide, apalutamide, or darolutamide.
• They should make sure there are no important cancer sites with low or absent PSMA uptake. His report is encouraging on this point, but the treating nuclear medicine team should review the actual PET images and not only the written report.

Plain answer

Main side effects to discuss

• Fatigue
• Dry mouth and sometimes taste change
• Nausea, constipation, or reduced appetite
• Lower blood counts: anemia, low platelets, or low white cells
• Kidney toxicity, less common but monitored
• Rarely, serious marrow suppression

Ask the oncologist these exact questions

1. “Does his PSMA PET show sufficiently strong uptake in all clinically important lesions, without PSMA-negative disease?”
2. “Are his current CBC, platelets, kidney function and liver function safe for Lu-177?”
3. “Given the extensive bone involvement and recent chemotherapy, what is his personal risk of marrow suppression?”
4. “What is the expected aim in his case: PSA reduction, pain relief, disease control, or all three?”
5. “Should he also receive denosumab or zoledronic acid, and does any painful bone lesion need local radiotherapy first?”
6. “When will response be assessed: symptoms, PSA after which cycle, and repeat imaging after how many cycles?”